The study provides valuable insights into the clinical validity of the Philips IntelliSpace Cognition platform for diagnosing mild cognitive impairment (MCI), demonstrating strong sensitivity and specificity in distinguishing MCI from cognitively normal groups. However, the exclusion of patients with common comorbidities such as sleep apnea or substance use may limit the platform’s generalizability in broader clinical contexts.
– Could the authors provide further discussion on how these exclusions might affect the applicability of their findings in real-world settings?